^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Gastric Adenocarcinoma
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Gastric cancer:...Preferred regimen...Fam-trastuzumab deruxtecan-nxki for HER2 overexpression positive adenocarcinoma
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

    Excerpt:
    ...- Pathologically documented adenocarcinoma of the stomach (clinical stage before surgery of AJCC I-III), gastroesophageal junction, or lower oesophagus (to include Type I Siewert only), with HER2 overexpression (IHC 3+ or IHC 2+/ISH+) based on local tissue testing results....
    Trial ID:
    DECIPHER
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or in combination with other agents in patients with HER2- expressing Gastric Cancer

    Excerpt:
    ...Disease Characteristics: Locally advanced, unresectable, or metastatic disease Pathologically documented adenocarcinoma of the stomach/GEJ/esophagus with HER2 overexpression (IHC 3+ or IHC 2+/ISH+)3. ...
    Trial ID:
    2019-004483-22